Free Cash Flow for Biogen (BIIB)
Free Cash Flow for Biogen (BIIB): headline value $2.14B · YoY -18.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
BIIB
Currently viewingFree Cash FlowSwitch metric
Latest period
$2.14B
YoY change
-18.5%
5Y CAGR
-11.6%
Peak year (2019)
$6.56B
Latest annual
$2.05B
Free Cash Flow history chart for Biogen (BIIB) from 1989 to 2025
Free Cash Flow history table for Biogen (BIIB) from 1989 to 2025
| Fiscal year | Period ended | Reported | Free Cash Flow | YoY |
|---|---|---|---|---|
| 2025 | $2.05B | -18.5% | ||
| 2024 | $2.52B | +103.6% | ||
| 2023 | $1.24B | +8.0% | ||
| 2022 | $1.14B | -66.2% | ||
| 2021 | $3.38B | -11.1% | ||
| 2020 | $3.81B | -42.0% | ||
| 2019 | $6.56B | +23.8% | ||
| 2018 | $5.30B | +43.9% | ||
| 2017 | $3.68B | -4.6% | ||
| 2016 | $3.86B | +25.6% | ||
| 2015 | $3.07B | +17.0% | ||
| 2014 | $2.63B | -325.6% | ||
| 2013 | -$1.16B | -171.6% | ||
| 2012 | $1.63B | +10.2% | ||
| 2011 | $1.48B | +1.6% | ||
| 2010 | $1.45B | +59.6% | ||
| 2009 | $909.25M | -29.4% | ||
| 2008 | $1.29B | +74.9% | ||
| 2007 | $736.53M | +14.6% | ||
| 2006 | $642.96M | +12.6% | ||
| 2005 | $571.13M | +59.4% | ||
| 2004 | $358.22M | -536.7% | ||
| 2003 | -$82.03M | -716.0% | ||
| 2002 | $13.32M | -89.0% | ||
| 2001 | $120.82M | -27.6% | ||
| 2000 | $166.82M | -10.3% | ||
| 1999 | $185.96M | +38.5% | ||
| 1998 | $134.23M | +116.2% | ||
| 1997 | $62.08M | -425.1% | ||
| 1996 | -$19.10M | -53.3% | ||
| 1995 | -$40.86M | +365.2% | ||
| 1994 | -$8.78M | -123.9% | ||
| 1993 | $36.80M | +9.2% | ||
| 1992 | $33.70M | -1448.0% | ||
| 1991 | -$2.50M | +525.0% | ||
| 1990 | -$400,000 | -96.2% | ||
| 1989 | -$10.60M | — |
Free Cash Flow values are taken from Biogen's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Biogen (BIIB) free cash flow is $2.05B – declined 18.5% year-over-year.
Across 2020–2025 (5 years), Biogen free cash flow produced a CAGR of -11.6% – with a net decline across the window.
Biogen free cash flow peaked at $6.56B in 2019; the latest annual figure is $2.05B in 2025 (68.8% below peak).
Across the available history, free cash flow reached its high of $6.56B in 2019 and its low of -$1.16B in 2013.
Biogen (BIIB) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $14.22B.
Biogen Free Cash Flow by Year
Biogen Free Cash Flow 2025: $2.05B
Biogen free cash flow in 2025 was $2.05B, declined 18.5% below 2024.
Biogen Free Cash Flow 2024: $2.52B
Biogen free cash flow in 2024 was $2.52B, surged 103.6% from 2023.
Biogen Free Cash Flow 2023: $1.24B
Biogen free cash flow in 2023 was $1.24B, grew 8.0% from 2022.
Biogen Free Cash Flow 2022: $1.14B
Biogen free cash flow in 2022 was $1.14B, plunged 66.2% below 2021.
Biogen Free Cash Flow 2021: $3.38B
Biogen free cash flow in 2021 was $3.38B.
See more financial history for Biogen (BIIB).
Sector peers — Free Cash Flow
Companies in the same sector as Biogen, ranked by their latest free cash flow.
| Company | Free Cash Flow | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $28.99B | Healthcare |
| Johnson & Johnson (JNJ) | $19.70B | Healthcare |
| AbbVie Inc. (ABBV) | $17.82B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $16.07B | Healthcare |
| Merck & Co., Inc. (MRK) | $12.36B | Healthcare |
| AstraZeneca PLC (AZN) | $11.77B | Healthcare |
| Eli Lilly and Company (LLY) | $8.97B | Healthcare |
| Amgen Inc. (AMGN) | $8.10B | Healthcare |
Frequently asked questions
What is Biogen's free cash flow?
Latest reported free cash flow for Biogen (BIIB) is $2.14B (period ending December 31, 2025).
How has Biogen free cash flow changed year-over-year?
Biogen (BIIB) free cash flow changed -18.5% year-over-year on the latest annual filing.
What is the long-term growth rate of Biogen free cash flow?
Biogen (BIIB) free cash flow compound annual growth rate is -11.6% over the most recent 5 years available.
When did Biogen free cash flow hit its highest annual value?
Biogen free cash flow reached its highest annual value of $6.56B in 2019.
What was Biogen free cash flow in 2024?
Biogen (BIIB) free cash flow in 2024 was $2.52B.
What was Biogen free cash flow in 2025?
Biogen (BIIB) free cash flow in 2025 was $2.05B.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
BIIB Overview
Company profile, financial tools, and key metrics
BIIB Revenue Counter
Earns $311.09 every second. See per minute, hour, and day.
BIIB Earnings Counter
Earns $41.01 per second net profit. See per minute, hour, and day.
BIIB Economic Scale
Exceeds Bermuda's GDP. Compare with world economies.
BIIB What If Invested
What if you had invested $1,000? See historical returns from any date.
BIIB How It Makes Money
Discover visual breakdown of $9.81B in revenue — where it comes from and where it goes.
BIIB Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BIIB Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BIIB Daily Price Character
Explosive · 48.1% historical win rate (green days). Streaks & record days.
BIIB Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BIIB Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.